GLP-1RA were initially developed to treat type 2 diabetes patients, in whom the effects upon glycemia and, moreover, weight loss, especially with long-acting GLP-1RA, were evident
Recent studies show that this class of drugs is effective in lowering risk of cardiovascular disease and improving sleep apnea and might be appropriate to treat fatty liver disease, Alzheimers disease, smoking cessation and substance use disorder
So, as you go into your 2026 renewal conversations, heres what you need to know about where GLP-1s stand, how they may affect employer plans, and the compliance questions you should help your clients think through
If scientific evidence is the priority, oral supplements have a clear advantage